参考文献/References:
[1] Jofre R,Rodriguez-Benitez P,Lopez-Gomez JM,et al.Inflammatory syndrome in patients on hemodialysis[J].J Am Soc Nephrol,2006,17(S3):274-280.
[2] Betjes MG.Immune cell dysfunction and inflammation in end-stage renal disease[J].Nat Rev Nephrol,2013,9(5):255-265.
[3] Catar R,Moll G,Kamhieh-Milz J,et al.Expanded hemodialysis therapy ameliorates uremia-induced systemic microinflammation and endothelial dysfunction by modulating VEGF,TNF-α and AP-1 signaling[J].Front Immunol,2021,12:774052.
[4] Ojeda R,Arias-Guillen M,Gomez M,et al.Study of biocompatibility of membranes in online hemodiafiltration[J].Blood Purif,2020,49(4):400-408.
[5] Liang M,Guo Q,Huang F,et al.Notch signaling in bone marrow-derived FSP-1 cells initiates neointima formation in arteriovenous fistulas[J].Kidney Int,2019,95(6):1347-1358.
[6] Onal EM,Afsar B,Covic A,et al.Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease[J].Hypertens Res,2019,42(2):123-140.
[7] Liakopoulos V,Jeron A,Shah A,et al.Hemodialysis-related changes in phenotypical features of monocytes[J].Sci Rep,2018,8(1):13964.
[8] Fukushi T,Yamamoto T,Yoshida M,et al.Enhanced neutrophil apoptosis accompanying myeloperoxidase release during hemodialysis[J].Sci Rep,2020,10(1):21747.
[9] Winterberg PD,Robertson JM,Kelleman MS,et al.T cells play a causal role in diastolic dysfunction during uremic cardiomyopathy[J].J Am Soc Nephrol.2019,30(3):407-420.
[10] Molina M,Allende LM,Ramos LE,et al.CD19+ B-cells,a new biomarker of mortality in hemodialysis patients[J].Front Immunol,2018,9:1221.
[11] Eleftheriadis T,Pissas G,Remoundou M,et al.Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin,inflammation,markers of iron status and resistance to erythropoietin[J].Int Urol Nephrol,2014,46(1):161-167.
[12] Zimmermann J,Herrlinger S,Pruy A,et al.Inflammation enhances cardiovascular risk and mortality in hemodialysis patients[J].Kidney Int,1999,55(2):648-658.
[13] Manghat P,Fraser WD,Wierzbicki AS,et al.Fibroblast growth factor-23 is associated with C-reactive protein,serum phosphate and bone mineral density in chronic kidney disease[J].Osteoporos Int,2010,21(11):1853-1861.
[14] Maraj M,Kusnierz-Cabala B,Dumnicka P,et al.Malnutrition,inflammation,atherosclerosis syndrome(MIA)and diet recommendations among end-stage renal disease patients treated with maintenance hemodialysis[J].Nutrients,2018,10(1):69.
[15] Razeghi E,Sahraian MA,Heidari R,et al.Association of inflammatory biomarkers with sleep disorders in hemodialysis patients[J].Acta Neurol Belg,2012,112(1):45-49.
[16] Raikou VD,Kyriaki D.The relationship between glycemic control,beta2-microglobulin and inflammation in patients on maintenance dialysis treatment[J].J Diabetes Metab Disord,2015,14:34.
[17] 王 冰.高通量血液透析对终末期肾衰患者营养状况及肾性贫血状况的影响[J].陕西医学杂志,2019,48(6):766-769.
[18] 张晓丽.血液透析联合血液灌注对糖尿病肾病患者血清空腹血糖、C反应蛋白、白细胞介素-6影响的临床研究[J].陕西医学杂志,2020,49(1):68-71.
[19] 刘志华,董 彬,李 颖.维持性血液透析患者中医证候分布与微炎症相关性的临床探讨[J].中医临床研究,2015,7(21):81-83.
[20] 陈杰彬,鲁 路,赖伟兰,等.补脾益肾、通腑化浊法对维持性血液透析患者营养不良及微炎症状态的影响[J].四川中医,2018,36(1):105-108.
[21] 卢占锋.肾康Ⅱ号对维持性血液透析患者微炎症状态影响的临床观察[J].中国中西医结合肾病杂志,2012,13(1):76-77.
[22] 左 琪,杨霓芝,王立新,等.中药对维持性血透患者微炎症影响的临床研究[J].云南中医学院学报,2006,29(3):18-21.
[23] 钟 建,王仕琦,唐 农.“浊毒”理论在慢性肾衰竭中的应用研究[J].西部中医药,2013,26(7):121-123.
[24] 陈秀娟,朱昭明,苏宝印.参芪清毒胶囊对血液透析患者营养指标、氧化应激、炎性因子、残余肾功能的影响[J].陕西中医,2021,42(3):334-337.
[25] 程延娜,安 智.益气利水活血方对终末期肾病维持性血液透析患者微炎症状态、凝血功能及心肌结构功能的影响[J].现代中西医结合杂志,2017,26(26):2861-2863.
[26] 程小丽,杨世峰,师锁江,等.黄芪附子方治疗慢性肾功能衰竭维持性血液透析疗效及对患者氧化应激、微炎症反应和生活质量的影响[J].陕西中医,2020,41(10):1436-1439.
[27] 梁同衍,刘 侠,胥正娟.四物汤对维持性血液透析患者微炎症状态的影响[J].中国医药指南,2013,11(15):14-15.
[28] 陶 静,华建武,蒋蕴琴,等.保肾片对维持性血液透析患者微炎症状态的影响[J].中西医结合心血管病电子杂志,2017,5(22):51-53.
[29] 瞿 伟,薛 莉,李 靖.倍生颗粒治疗血液透析患者微炎症状态临床观察[J].辽宁中医药大学学报,2011,13(9):9-10.
[30] 张 倩.尿毒清颗粒治疗维持性血液透析患者微炎症状态的临床观察[J].现代诊断与治疗,2019,30(10):1617-1618.
[31] 孙馥云,李丽华,孙文英,等.百令和复方α-酮酸片联用对维持性血液透析患者微炎症状态影响的研究[J].中国实用内科杂志,2008,28(12):1080.
[32] 禚丽琴,姚丹丹,仇方忻.金水宝片对维持性血液透析患者微炎症状态及营养状况的影响[J].中国医药导刊,2019,21(11):679-682.
[33] 付会玲,蔡 威,陈文莉.白芍总苷改善维持性血液透析患者微炎症状态的临床研究[J].临床肾脏病杂志,2018,18(9):526-530.
[34] 郑文彬.苦参素胶囊对维持性血液透析患者微炎症状态的影响[D].武汉:湖北中医学院,2009.
[35] 周丽美,金 烈,朱潮涌,等.丹参酮ⅡA磺酸钠对血液透析患者血小板聚集率及微炎症状态的影响[J].浙江实用医学,2016,21(2):98-99.
[36] 罗志毅,黄 新,包国荣.大黄中主要成分清除超氧阴离子自由基的ESR研究[J].中华中医药学刊,2007,25(3):612-614.
[37] 王梅芳,刘 猛.大黄对维持性血液透析患者微炎症和营养不良的影响[J].实用药物与临床,2012,15(8):486-487.
[38] 曲晓璐,戴 芹,漆映辉,等.黄芪对血液透析患者氧化应激的影响[J].中西医结合学报,2008,6(5):468-472.
[39] 于国庆,孙兆峰,王 凯,等.太极拳养生八式对维持性血液透析患者康复治疗效果[J].山东第一医科大学学报,2022,43(8):588-595.
[40] 陈慧玉,叶 慧,宫 琴,等.中医养生对血透患者微炎症状态的影响[J].临床医药文献电子杂志,2019,6(65):16-17.
相似文献/References:
[1]赵倩倩,王惠玲,苏衍进△.糖肾一号方改善早期糖尿病肾病微炎症状态临床研究*[J].陕西中医,2020,(4):443.
ZHAO Qianqian,WANG Huiling,SU Yanjin..Clinical study of Tangshen 1st recipe in improving micro-inflammatory state of early diabetic nephropathy[J].,2020,(4):443.
[2]郝 静,夏京华.加味桃红四物汤联合左卡尼汀对维持性血液透析患者营养状况的影响[J].陕西中医,2021,(7):903.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.024]
[3]李慧灵,张建德,叶 静,等.加味玉液汤治疗气阴两虚型糖尿病肾病慢性肾衰竭疗效及对患者微炎症状态的影响[J].陕西中医,2022,(8):1064.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.018]
[4]任剑雄,韦淇元,梁建亮.参芪真武汤加味治疗原发性肾病综合征疗效及对患者肾功能、微炎状态、凝血纤溶功能的影响[J].陕西中医,2024,(8):1052.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.009]
REN Jianxiong,WEI Qiyuan,LIANG Jianliang.Effect of Shenqi Zhenwu decoction on primary nephrotic syndrome and its influence on renal function,micro-inflammatory state,coagulation and fibrinolytic function[J].,2024,(4):1052.[doi:DOI:10.3969/j.issn.1000-7369.2024.08.009]
[5]吴斯琦,丁萌譞,舒占钧.参芪地黄汤加味对脂多糖诱导人肾小管上皮细胞TLRs/NF-κB信号通路的影响[J].陕西中医,2025,46(3):320.[doi:DOI:10.3969/j.issn.1000-7369.2025.03.007]
WU Siqi,DING Mengxuan,SHU Zhanjun.Effect of Shenqi Dihuang decoction on lipopolysaccharide induced TLRs/NF-κB signaling pathway in HK-2 cells[J].,2025,46(4):320.[doi:DOI:10.3969/j.issn.1000-7369.2025.03.007]
[6]林玉洁,张成亮,王林琳,等.固本通络汤联合血液透析治疗急性肾衰竭临床研究[J].陕西中医,2025,46(4):467.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.007]
LIN Yujie,ZHANG Chengliang,WANG Linlin,et al.The effects of Guben Tongluo decoction combined with hemodialysis in treatment of patients with acute renal failure[J].,2025,46(4):467.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.007]